Center for Medical Laboratory Science, Affiliated Hospital of Youjiang Medical University for Nationalities, Guangxi, 533000, China.
Baise Key Laboratory for Research and Development on Clinical Molecular Diagnosis for High-Incidence Diseases, Guangxi, 533000, China.
Clin Invest Med. 2024 Sep;47(3):27-37. doi: 10.3138/cim-2024-2711. Epub 2024 Aug 27.
Ischemic stroke (IS) is a global health concern, often tied to dyslipidemia and vascular endothelial dysfunction. MicroRNA-34a (miR-34a) was reported to be up-regulated in the blood samples of patients with IS, but the specific role of miR-34a and methylenetetrahydrofolate reductase (MTHFR) in IS remains to be elucidated.
We studied 143 subjects: 71 IS patients, and 72 healthy controls. Human umbilical vein endothelial cells (HUVECs) were cultured and transfected with a miR-34a mimic, inhibitor, or negative control. The miR-34a expression in serum and HUVECs was quantified via quantitative reverse transcription polymerase chain reaction (qRT-PCR). Viability and apoptosis of HUVECs were assessed using CCK-8 assay and flow cytometry. The expression levels of bcl-2, bax, cyt-c, cleaved caspase 3, MTHFR, and homocysteine were measured by Western blot or enzyme-linked immunosorbent assay (ELISA). The relationship between miR-34a and MTHFR was verified by luciferase reporter assay. The levels of MTHFR and homocysteine in serum were examined by ELISA.
MiR-34a expression was increased in IS patients and inhibited viability of HUVECs while promoting their apoptosis. Overexpression of miR-34a up-regulated pro-apoptotic proteins (bax, cyt-c and cleaved caspase 3) and down-regulated anti-apoptotic protein bcl-2 in HUVECs. MTHFR was identified as the downstream target of miR-34a and its expression was reduced by miR-34a overexpression, while homocysteine levels increased. Consistently, MTHFR levels were lower and homocysteine levels were higher in IS patients compared with controls.
Our results suggest that up-regulated miR-34a plays a role in the pathogenesis of IS, potentially through inhibiting MTHFR expression and increasing homocysteine in endothelial cells. Therefore, miR-34a might be a therapeutic target for IS.
缺血性脑卒中(IS)是一个全球性的健康问题,通常与血脂异常和血管内皮功能障碍有关。有报道称,miR-34a 在 IS 患者的血液样本中上调,但 miR-34a 和亚甲基四氢叶酸还原酶(MTHFR)在 IS 中的具体作用仍有待阐明。
我们研究了 143 例受试者:71 例 IS 患者和 72 例健康对照者。培养人脐静脉内皮细胞(HUVECs)并转染 miR-34a 模拟物、抑制剂或阴性对照。通过实时定量聚合酶链反应(qRT-PCR)定量血清和 HUVECs 中的 miR-34a 表达。通过 CCK-8 测定和流式细胞术评估 HUVECs 的活力和凋亡。通过 Western blot 或酶联免疫吸附测定(ELISA)测定 bcl-2、bax、cyt-c、cleaved caspase 3、MTHFR 和同型半胱氨酸的表达水平。通过荧光素酶报告基因测定验证 miR-34a 与 MTHFR 的关系。通过 ELISA 检测血清中 MTHFR 和同型半胱氨酸的水平。
IS 患者 miR-34a 表达增加,抑制 HUVECs 活力,促进其凋亡。miR-34a 过表达上调促凋亡蛋白(bax、cyt-c 和 cleaved caspase 3),下调抗凋亡蛋白 bcl-2。MTHFR 被鉴定为 miR-34a 的下游靶基因,其表达被 miR-34a 过表达下调,同时同型半胱氨酸水平升高。一致地,IS 患者 MTHFR 水平较低,同型半胱氨酸水平较高。
我们的结果表明,上调的 miR-34a 在 IS 的发病机制中起作用,可能通过抑制内皮细胞中 MTHFR 的表达和增加同型半胱氨酸。因此,miR-34a 可能是 IS 的治疗靶点。